Case Report

Acetazolamide assisted rapid resolution of optic disc pit maculopathy in a 15 year old child

Ruchir Amit Mehta1,*, Neha Raka Mehta1, Samip Mehta1, Amit Mehta1

1 Mehta Superspeciality Eye Hospital, Jamnagar, Gujarat, India

ARTICLE INFO

Article history:
Received 10-04-2020
Accepted 10-05-2020
Available online 22-12-2020

Keywords:
Acetazolamide
Optic disc pit maculopathy
Paediatric patient

ABSTRACT

A 15 years old girl presented to us with diminution of vision within 4 days of onset. The child underwent relevant investigations and a diagnosis of optic disc pit maculopathy (OPD-M) was made. The parents refused surgical intervention and so we started the child on oral acetazolamide. She was kept under repeated and close follow-ups. We noticed rapid resolution of optic disc pit maculopathy within 2 months of presentation with complete visual recovery. Oral acetazolamide was tapered during the course of 2 months. We conclude that although numerous treatment modalities have been described for optic disc pit maculopathy, a trial of oral acetazolamide can be offered in cases of optic disc pit maculopathy in paediatric patients.

© This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

1. Introduction

Optic disc pit is a rare congenital anomaly resulting from an imperfect closure of the superior edge of the embryonic fissure that can be congenital or acquired.1,2 The incidence of optic disc pit has been reported to be about 1 in 11,000, being bilateral in 15% of the cases.3 Optic disc pits may be asymptomatic, but they may also present with macula related complications such as serous retinal detachment or cystoid macular edema affecting visual acuity in nearly 50% of the cases.4 Various treatment alternatives have been described for optic disc pit related maculopathy including conservative management, laser photocoagulation, macular buckling surgery, vitrectomy with or without internal limiting membrane (ILM) peeling, gas tamponade and the combination of them. Acetazolamide therapy has been studied in treatment of optic disc pit maculopathy, with variable success.5 Herein, we report a rare case of rapid resolution of optic disc pit maculopathy and complete visual recovery in a 15 years old girl who was started on oral acetazolamide within 4 days of visual impairment.

2. Case History

A previously healthy 15-year-old girl, weighing 40 kg, came to us with complaint of sudden painless decrease in vision in right eye since 4 days. The patient had undergone fundus photography, spectral domain optical coherence tomography (SD-OCT) and fundus fluorescein angiography elsewhere. Her best-corrected visual acuity (BCVA) was 20/400, <N36 in the right eye and 20/20, N6 in the left eye. Her intraocular pressures were 13 mmHg in both eyes. Her anterior segment examination was unremarkable. On fundus examination, serous macular detachments extending to the optic disc were noted in right eye but disc pit could not be localized. There were no pathological changes in left eye (Figure 1 a, b). SD-OCT (Cirrus, Carl Zeiss Meditec. Inc.) imaging revealed macular schisis with neurosensory detachment extending to optic nerve in right eye (Figure 2 a, b). The FFA images showed no abnormal findings (Figure 3 a, b). The diagnosis of optic disc pit maculopathy (ODP-M) was made for right eye.

As the parents refused any laser/surgical intervention, patient was started on oral acetazolamide 250 mg three times a day, after ruling out all contraindications, under guarded visual prognosis. The patient was reviewed after
Fig. 1: a) Fundus image of right eye showing well delineated areas of subretinal fluid (denoted by * and **). b) Fundus image of the left eye which showed no pathological changes.

Fig. 2: a) SD-OCT image of right eye showing subfoveal neurosensory detachment extending to the optic nerve nasally along with retinal schisis. b) SD-OCT image of left eye showing normal foveal contour and healthy photoreceptor layers.

Fig. 3: (a, b) Fundus fluorescein angiography of right and left eyes in late A-V phase showing no abnormal pooling or leaking.

Fig. 4: a) SD-OCT image of right eye at first follow-up after 2 weeks showing resolved retinal schisis and minimal subretinal fluid with damaged photoreceptor layers subfoveally and nasal to fovea extending to the disc. b) SD-OCT image of right eye at second follow-up, 2 weeks after the first follow-up showing resolved subretinal fluid, regenerating photoreceptor layers. c) SD-OCT image of right eye at third follow-up, 1 month after the second follow-up showing resolved subretinal fluid and regenerated photoreceptor layers.
2 weeks, she was symptomatically better with BCVA in right eye improved to 20/120. SD-OCT of the right eye showed minimal subfoveal subretinal fluid, with resolution of macular schisis but complete loss of photoreceptor layers till the optic disc (Figure 4 a). On further follow-up after 2 weeks, the patient’s visual acuity had improved to 20/40.

SD-OCT at this follow-up showed regenerated external limiting membrane (ELM) but absent ellipsoid zone (EZ) and interdigitation zone (IZ) nasally (Figure 4 b). Finally, visual acuity of the right eye was 20/20 at 2 months after presentation and initiation of treatment. Fundus examination of the right eye showed good foveal reflex with flat retina and no posterior vitreous detachment (PVD). SD-OCT showed complete resolution of subretinal fluid with complete regeneration of ELM, EZ and IZ within 2 months of presentation (Figure 4 c). 250 mg oral acetazolamide was tapered to twice daily at 1 month, once daily at 1 1/2 months and eventually stopped once there was complete resolution of the maculopathy at 2 months post presentation. The patient maintained her vision and fundal findings on her last visit 12 months from presentation.

3. Discussion

The source of submacular fluid in OPD-M is controversial and has been suggested to arise from cerebrospinal fluid or liquefied vitreous entering the submacular space through a communication either between the subarachnoid space and the optic pit or through a fenestration in the membrane overlying the pit. There are a few cases reported in literature of spontaneous resolution of maculopathy due to optic disc pit in children\(^2\) and adults,\(^1,8\)–\(^10\) 25% of ODP-Ms do resolve spontaneously, but mostly these result in poor visual outcome, especially if subretinal fluid persists for more than 3 months.\(^2\) As the disease mechanism is still not understood, the management strategy remains debatable. Various treatment alternatives have been described for ODP-M including conservative management, laser photoagulation, macular buckling surgery, vitrectomy +/- internal limiting membrane (ILM) peeling, gas tamponade and the combination of them. It has been suggested that PVD releases the traction on the fenestration overlying the disc pit and can lead to resolution of ODP-M but there was no PVD in our case at any point. Acetazolamide therapy has been studied in optic disc pit maculopathy as a standalone treatment or an adjuvant therapy with variable success.\(^5\)

Pradeep S Prasad and colleagues\(^5\) first reported use of oral acetazolamide as a standalone therapy for resolution of ODP-M in a 9-year-old child with Incontinentia Pigmenti. They noted complete resolution of ODP-M with a visual outcome of 20/25 after 13 months of oral therapy. Carbonic anhydrase inhibitors (CAIs) improve retinal adhesion and induce resorption of subretinal fluid by producing acidification of the subretinal space.\(^11\) In addition, acetazolamide also inhibits the carbonic anhydrase enzyme in the choroid plexus, resulting in decreased cerebrospinal fluid production and reduction in intracranial pressure.\(^12\) Assuming the fluid in ODP-M originates from the pressure gradient between the subarachnoid space and the eye, lowering the ICP using CAIs could decrease the fluid accumulation in the macular region. Furthermore, acetazolamide also decreases IOP, which might affect the pressure gradient at the lamina cribrosa. The dosage of 250 mg thrice daily for our patient was decided based on US-FDA approved maximum dosage of 1000 mg/ day (10-30 mg/ kg/ day) of oral acetazolamide for children. We also referred to previous reports of use of oral acetazolamide in paediatric patients and the dosage used for those patients,\(^5,13,14\) Prasad et al. used 125 mg of oral acetazolamide for 13 months in their 9 years old patient. Osigian et al. and Martins D. et al. have each reported a single case of adjuvant therapy with oral acetazolamide post vitrectomy in case of ODP-M.\(^13,14\) Osigian et al. placed their 86 kg 12 years old patient on 500 mg of extended-release acetazolamide tablets three times a day. Although duration of acetazolamide therapy was not clearly reported in their study. Considering the speed of improvement in our patient it seems less likely to be a case of spontaneous resolution and more of acetazolamide assisted one. It is noteworthy that the patient has stayed symptom free, off acetazolamide therapy, for 12 months.

Despite numerous case reports offering different treatment modalities, the best method has not yet been determined for paediatric cases with ODP-M. Low-dose oral acetazolamide should be considered in the management of ODP-M, given the rapid and sustained results demonstrated in this case and the potentially decreased risk compared with other treatment strategies, especially in paediatric patients.

4. Source of Funding

None.

5. Conflict of Interest

The authors declare that there is no conflict of interest regarding the publication of this article.

References


Author biography

**Ruchir Amit Mehta**, Vitreoretina Consultant

**Neha Raka Mehta**, Pediatric Ophthalmologist

**Samip Mehta**, Cornea Consultant

**Amit Mehta**, Phaco and Refractive Surgeon

Cite this article: Mehta RA, Mehta NR, Mehta S, Mehta A. Acetazolamide assisted rapid resolution of optic disc pit maculopathy in a 15 year old child. *Indian J Clin Exp Ophthalmol* 2020;6(4):650-653.